Sublingual Photobiomodulation in Parkinson's Disease

Evaluation of the Concentrations of Inflammatory, Protein and Oxidative Biomarkers of Parkinson's Disease After Photobiomodulation From Sublingual Laser Application - Clinical, Randomized and Blind Test

This study evaluates the use of photobiomodulation in the treatment of patients with Parkinson's disease. Half of participants will receive treatment with low level laser therapy and exercises in combination, while the other half will receive a placebo laser combined with exercises.

Inclusion Criteria:

• patients with Parkinson's disease diagnosed with the criteria of the UK Parkinsons' Disease Society Brain Bank Clinical Diagnostic Criteria
• In the stages I to III of the disease according to Hoehn & Yahr's Parkinson's disease staging scale - modified;
• Individuals of both sexes,
• with more than 50 years
• who sign the informed consent form

Exclusion Criteria:

• patients who present some adverse event during the development of the study,
• Who have another associated neurodegenerative disease,
• Have blood dyscrasia, HIV, heart failure, hepatic or renal insufficiency, infections, neoplasias, respiratory disorders, hypophysis and hypothalamus problems.
• Who fail to understand or perform procedures correctly because of physical and mental limitations.